Abstract: OBJECTIVE To observe the clinical efficacy of Jiubiying Decoction combined with DP regimen (docetaxel+cisplatin) in the treatment of elderly patients with advanced non-small cell lung cancer. METHODS 100 elderly patients with advanced non-small cell lung cancer were randomly divided into treatment group and control group， 50 cases in each group. The control group was treated with DP chemotherapy， and the treatment group was given by Jiubiying Decoction on the basis of control group. All of them were treated with 21 days as a cycle and 4 cycles were observed. The changes of tumor size， TCM symptom score， side effects， serum p53， Survivin level and immune status were observed before and after treatment. RESULTS In terms of solid tumor changes， treatment group was superior to control group in total effective and disease control rate (P<0.05). After treatment， the TCM symptom scores， serum p53 and Survivin levels in two groups were lower than those before treatment (P<0.01)， the degree of reduction in treatment group was higher than that in control group (P<0.01). For immune function， the levels of CD3⁺， CD4⁺， CD4⁺/CD8⁺ in treatment group were significantly higher than those before treatment and control group (P<0.01). For side effects， the cases of myelosuppression and liver damage in treatment group were less than those in control group (P<0.05). CONCLUSION Jiubiying Decoction combined with DP regimen can better control tumor size， improve clinical symptoms， and decrease serum p53 and Survivin levels in elderly patients with advanced non-small cell lung cancer， and have synergistic and attenuating effects.